Savara Heads Into PDUFA Day With Bears Dug In

SVRA reports August 12 results as the stock trades at $5.57 — down 8% over the past month but recovering modestly over the past week — with short sellers holding one of the largest positions in small-cap biotech.

Short interest is the defining feature of this setup. Bears have built a position equal to 17% of free float, a level ORTEX flags as high, and that position has grown roughly 13% over the past month as August's FDA decision date approached. The ORTEX short score has held in the mid-70s for two weeks, ranking in the bottom 7th percentile across the universe — a signal that the aggregate short-side picture is more adverse than nearly all peers. Yet the borrow market itself tells a calmer story. Availability is ample at 336% — meaning more than three shares are available to borrow for every one already shorted — and the cost to borrow is just 0.54%, near the floor of its recent range. Shorts are entrenched but face no squeeze pressure from the lending market.

Options positioning adds a layer of caution. Puts outnumber calls at a ratio of 1.64, modestly above the 20-day average of 1.51, though the z-score of 0.33 suggests this is elevated but not extreme relative to SVRA's own history — the 52-week high on the put/call ratio was 3.23. The heavier put loading that built through late July has eased slightly into the print, but defensive positioning clearly outweighs bullish bets.

The bull and bear cases are unusually binary for a small-cap name. Bulls point to FDA clearance momentum for Molbreevi — the inhaled molgramostim targeting autoimmune pulmonary alveolar proteinosis — citing positive regulatory interactions, a resubmitted BLA with a stronger CMC package via Fujifilm Diosynth, and $225 million in recent financing that funds a commercial launch. The consensus mean target from analysts, last compiled in June, was roughly $10.94 — nearly double the current price — and the direction of analyst revisions through late 2025 was uniformly upward, with multiple firms lifting targets by 25-40% in the months following mid-year data. Bears counter that Molbreevi's addressable pool is narrow — around 5,500 confirmed aPAP patients — leaving limited commercial upside even under approval, and that the stock has drifted lower despite positive regulatory signals. The analyst data is dated (last consolidated June 2026), so the exact consensus skew heading into today's event is uncertain.

One institutional data point stands out. Vanguard Capital Management initiated a position of nearly 8.8 million shares — reported as of June 30 — while BlackRock added 1.2 million shares as recently as July 31. Against that backdrop, the CFO sold roughly $3.3 million of stock in late June, though the trades appear routine in structure and timing relative to the regulatory calendar.

The earnings print — really a regulatory outcome wrapper — is less a test of quarterly financials and more a live referendum on whether the FDA will grant Molbreevi approval, and whether the commercial case for a rare-disease launch with 5,500 identifiable patients can justify a valuation that currently sits well above the stock price in analyst models but well below it in the short book.